Asad Dean, MD

An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address despite raising platelet counts. An expert discusses how rilzabrutinib’s oral administration and broad tolerability make it a practical treatment option while emphasizing the need for long-term efficacy and safety data to strengthen clinical confidence.

An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address despite raising platelet counts.

An expert discusses how rilzabrutinib’s covalent reversible binding mechanism provides a favorable safety profile with only manageable grade 1 to 2 toxicities and no cardiovascular or bleeding complications, unlike earlier irreversible Bruton tyrosine kinase (BTK) inhibitors.

An expert discusses how the phase 3 LUNA 3 trial demonstrated that rilzabrutinib achieved durable platelet responses in 23% of patients while also being the first prospective trial to show significant improvements across all quality-of-life metrics.

An expert discusses how current immune thrombocytopenia (ITP) treatments such as corticosteroids, rituximab, and fostamatinib have significant tolerability issues and fail to provide sustained platelet responses or address quality-of-life concerns.

An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase (BTK) inhibitor, targets the autoimmune pathophysiology of immune thrombocytopenia (ITP) by modulating B cells, macrophages, and reducing pro-inflammatory cytokines.